Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether methotrexate plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Methotrexate · people with chronic plaque psoriasis
Any systemic treatment may leads to higher methotrexate compared with placebo (low certainty).
2 findings from 1 review
Intervention not reported
Methotrexate (1 RCT; 50 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes methotrexate (1 RCT; 50 participants) (very low certainty).
1 finding from 1 review
Methotrexate · healthcare staff who handle infusional hazardous drugs
It is very uncertain whether closed‐system transfer device plus safe handling changes methotrexate compared with safe handling alone (very low certainty).
1 finding from 1 review
RR 0.84 [0.58, 1.22]
Studies not reported
Very low
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of chronic GVHD · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
1 finding from 1 review
Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) probably leads to lower GI side effects (nausea, vomiting, abdominal pain) compared with placebo (moderate certainty).
1 finding from 1 review
Liver toxicity (incidence of transaminase elevation) · Patients receiving methotrexate for rheumatoid arthritis
Folic acid probably leads to lower liver toxicity (ie, incidence of transaminase elevation) compared with placebo (moderate certainty).
1 finding from 1 review
Haematological disorders (neutropenia, etc) · Patients receiving methotrexate for rheumatoid arthritis
Folic acid showed no clear difference in haematological disorders (incidence of neutropenia, etc) compared with placebo (low certainty).
1 finding from 1 review